ESMO-话题@MedSci

#ESMO#

214篇内容 | 5262人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1281015, encodeId=f4c7128101531, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【2019 ESMO】放化疗联合帕博利珠单抗治疗局部晚期食管鳞癌, objectType=article, longId=181035, objectId=c7c318103504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7c318103504, replyNumber=0, likeNumber=101, createdTime=2019-10-14, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7c318103504, moduleTitle=【2019 ESMO】放化疗联合帕博利珠单抗治疗局部晚期食管鳞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7c318103504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281014, encodeId=fe04128101464, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO重磅：一线双免疫联合治疗完胜化疗, objectType=article, longId=181033, objectId=fe5d181033f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe5d181033f2, replyNumber=0, likeNumber=65, createdTime=2019-10-14, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe5d181033f2, moduleTitle=ESMO重磅：一线双免疫联合治疗完胜化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe5d181033f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281013, encodeId=b5c41281013c4, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【2019 ESMO】专注胃癌发病机制基础研究，为胃癌治疗提供新思路, objectType=article, longId=180887, objectId=949818088e62, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=949818088e62, replyNumber=0, likeNumber=80, createdTime=2019-10-12, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=949818088e62, moduleTitle=【2019 ESMO】专注胃癌发病机制基础研究，为胃癌治疗提供新思路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=949818088e62)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281012, encodeId=f9841281012b4, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好, objectType=article, longId=180793, objectId=fd6a180e93a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd6a180e93a8, replyNumber=0, likeNumber=69, createdTime=2019-10-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd6a180e93a8, moduleTitle=ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd6a180e93a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281011, encodeId=217b128101130, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=刚刚结束的ESMO会议，盘点下结直肠癌海报专场的8个研究！, objectType=article, longId=180715, objectId=d5a0180e1534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5a0180e1534, replyNumber=0, likeNumber=78, createdTime=2019-10-10, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5a0180e1534, moduleTitle=刚刚结束的ESMO会议，盘点下结直肠癌海报专场的8个研究！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5a0180e1534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281010, encodeId=57c91281010dd, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO|未雨绸缪——HER2阳性乳腺癌，别等疾病复发转移, objectType=article, longId=180697, objectId=623d18069eb4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623d18069eb4, replyNumber=0, likeNumber=75, createdTime=2019-10-10, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623d18069eb4, moduleTitle=2019 ESMO|未雨绸缪——HER2阳性乳腺癌，别等疾病复发转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=623d18069eb4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281009, encodeId=5488128100947, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【2019 ESMO】哌柏西利联合内分泌治疗 vs 卡培他滨治疗HR+/HER2-晚期乳腺癌——疗效优异，生活质量可期, objectType=article, longId=180685, objectId=9c2e180685de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2e180685de, replyNumber=0, likeNumber=0, createdTime=2019-10-10, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2e180685de, moduleTitle=【2019 ESMO】哌柏西利联合内分泌治疗 vs 卡培他滨治疗HR+/HER2-晚期乳腺癌——疗效优异，生活质量可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2e180685de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281008, encodeId=1a0a128100865, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2019|中国原研新抗原肿瘤疫苗新成果, objectType=article, longId=180683, objectId=4f0f180683ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f0f180683ca, replyNumber=0, likeNumber=83, createdTime=2019-10-10, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f0f180683ca, moduleTitle=ESMO 2019|中国原研新抗原肿瘤疫苗新成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f0f180683ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281007, encodeId=e53d128100e29, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【2019 ESMO】林榕波教授团队报道四药联合方案治疗晚期胃癌, objectType=article, longId=180680, objectId=779218068058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=779218068058, replyNumber=0, likeNumber=87, createdTime=2019-10-10, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=779218068058, moduleTitle=【2019 ESMO】林榕波教授团队报道四药联合方案治疗晚期胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=779218068058)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281006, encodeId=1b4b128100610, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO：癌症新闻大爆炸, objectType=article, longId=180597, objectId=e30118059e6c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e30118059e6c, replyNumber=0, likeNumber=81, createdTime=2019-10-08, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e30118059e6c, moduleTitle=2019 ESMO：癌症新闻大爆炸, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e30118059e6c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281005, encodeId=c2981281005e1, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019年ESMO：Ivosidenib显著改善晚期mIDH1胆管癌患者的生存率, objectType=article, longId=180572, objectId=59da1805e210, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59da1805e210, replyNumber=0, likeNumber=60, createdTime=2019-10-07, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59da1805e210, moduleTitle=2019年ESMO：Ivosidenib显著改善晚期mIDH1胆管癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59da1805e210)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281004, encodeId=12fd128100482, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌, objectType=article, longId=180570, objectId=29001805e099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29001805e099, replyNumber=0, likeNumber=83, createdTime=2019-10-07, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29001805e099, moduleTitle=2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29001805e099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281003, encodeId=818c128100335, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效, objectType=article, longId=180569, objectId=13a6180569e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13a6180569e0, replyNumber=0, likeNumber=62, createdTime=2019-10-07, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13a6180569e0, moduleTitle=2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13a6180569e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281002, encodeId=1247128100260, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期, objectType=article, longId=180568, objectId=34561805686b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34561805686b, replyNumber=0, likeNumber=0, createdTime=2019-10-07, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34561805686b, moduleTitle=2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34561805686b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281001, encodeId=77cb128100121, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, objectType=article, longId=180550, objectId=a9941805506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9941805506a, replyNumber=0, likeNumber=106, createdTime=2019-10-07, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9941805506a, moduleTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9941805506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281000, encodeId=824f1281000c1, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO：肺癌脑转移的预测提供新的探索途径, objectType=article, longId=180463, objectId=a9c91804639f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9c91804639f, replyNumber=0, likeNumber=72, createdTime=2019-10-05, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9c91804639f, moduleTitle=ESMO：肺癌脑转移的预测提供新的探索途径, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9c91804639f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280999, encodeId=2705128099940, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019ESMO|基于ADJUVANT研究建立的MEDUSA模型——将助力EGFR突变早期肺癌术后的精准辅助治疗, objectType=article, longId=180460, objectId=b398180460d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b398180460d6, replyNumber=0, likeNumber=0, createdTime=2019-10-05, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b398180460d6, moduleTitle=2019ESMO|基于ADJUVANT研究建立的MEDUSA模型——将助力EGFR突变早期肺癌术后的精准辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b398180460d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280998, encodeId=3fdd128099882, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【ESMO 2019】新型ALK抑制剂WX-0593片的I期研究结果揭晓, objectType=article, longId=180459, objectId=8e4a1804599f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e4a1804599f, replyNumber=0, likeNumber=84, createdTime=2019-10-05, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e4a1804599f, moduleTitle=【ESMO 2019】新型ALK抑制剂WX-0593片的I期研究结果揭晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e4a1804599f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280997, encodeId=5714128099e4a, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=“氟维司群+”频频亮相ESMO, MONARCH-2研究再证氟维司群联合治疗改善OS, objectType=article, longId=180458, objectId=cfa118045850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfa118045850, replyNumber=0, likeNumber=57, createdTime=2019-10-05, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfa118045850, moduleTitle=“氟维司群+”频频亮相ESMO, MONARCH-2研究再证氟维司群联合治疗改善OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfa118045850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280996, encodeId=7041128099611, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO |TKI治疗论坛：中外大咖台论道，引领肠癌、肝癌治疗新理念, objectType=article, longId=180454, objectId=2c23180454c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c23180454c6, replyNumber=0, likeNumber=0, createdTime=2019-10-05, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c23180454c6, moduleTitle=2019 ESMO |TKI治疗论坛：中外大咖台论道，引领肠癌、肝癌治疗新理念, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c23180454c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ESMO

2020-05-29

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【2019 ESMO】放化疗联合帕博利珠单抗治疗局部晚期食管鳞癌

2019-10-14

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO重磅：一线双免疫联合治疗完胜化疗

2019-10-14

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【2019 ESMO】专注胃癌发病机制基础研究，为胃癌治疗提供新思路

2019-10-12

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好

2019-10-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

刚刚结束的ESMO会议，盘点下结直肠癌海报专场的8个研究！

2019-10-10

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO|未雨绸缪——HER2阳性乳腺癌，别等疾病复发转移

2019-10-10

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【2019 ESMO】哌柏西利联合内分泌治疗 vs 卡培他滨治疗HR+/HER2-晚期乳腺癌——疗效优异，生活质量可期

2019-10-10

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2019|中国原研新抗原肿瘤疫苗新成果

2019-10-10

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【2019 ESMO】林榕波教授团队报道四药联合方案治疗晚期胃癌

2019-10-10

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO：癌症新闻大爆炸

2019-10-08

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019年ESMO：Ivosidenib显著改善晚期mIDH1胆管癌患者的生存率

2019-10-07

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌

2019-10-07

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效

2019-10-07

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期

2019-10-07

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期

2019-10-07

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO：肺癌脑转移的预测提供新的探索途径

2019-10-05

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019ESMO|基于ADJUVANT研究建立的MEDUSA模型——将助力EGFR突变早期肺癌术后的精准辅助治疗

2019-10-05

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【ESMO 2019】新型ALK抑制剂WX-0593片的I期研究结果揭晓

2019-10-05

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

“氟维司群+”频频亮相ESMO, MONARCH-2研究再证氟维司群联合治疗改善OS

2019-10-05

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO |TKI治疗论坛：中外大咖台论道，引领肠癌、肝癌治疗新理念

2019-10-05

科室
- - 订阅+
  - 更多科室
工具
服务